Only eight percent of CNS drugs will reach approval, in part because of the high adverse effects standards.
Pierre Geoffroy
Advertisement
Articles by Pierre Geoffroy
Advertisement
Latest Updated Articles
CNS Drug Liabilities in Early Phase Clinical TrialsPublished: May 1st 2013 | Updated:
Advertisement
Advertisement
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
